Abstract
It is a well-known that a significant part in the structure of the digestive system diseases in children compounds disorders of the biliary tract, which are based on violations of the regulation of bile production and bile secretion. The topical issue is the search for safe and effective drugs that can prevent the transformation of biliary disorders into organic pathology, including cholecystitis, gallstone disease. One of such drugs is ursodeoxycholic acid (UDCA), which is actively use in pediatrics due to its hepatoprotective, immunomodulatory, choleretic, anticholestatic and other properties. The results of the literature review indicate that UDCA therapy provides various clinical effects: it improves liver function by lowering the level of liver enzymes, prevents the progression of liver diseases. In addition, its influence on the transformation of functional changes into organic pathology, especially in patients with diseases of the hepatobiliary tract associate with cholestasis, and is an alternative option for the treatment of chronic liver disease. Proven therapeutic efficacy, high quality and safety of UDCA create the prospect of including this drug in the treatment of children with functional and organic diseases of the liver and biliary tract. No conflict of interests was declared by the authors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
